Vitae Pharmaceuticals Inc.

(VTAE) Trade

By |

Profile

Vitae Pharmaceuticals Inc was incorporated in Delaware in May 2001. The Company is a clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for diseases in which there are significant unmet medical needs. The Company is developing a robust and growing portfolio of novel product candidates internally generated by Contour, its proprietary structure-based drug discovery platform. The Company's product candidate include VTP-43742, a first in class oral small molecule, which is being developed for the treatment of psoriasis as well as multiple autoimmune disorders, and is currently being studied in a Phase 2a proof-of-concept clinical trial. The Company's other product candidate is VTP-38543 for the treatment of atopic dermatitis, which is in Phase 2a clinical development. The Company also has a product candidate, VTP-36951, in pre-clinical development for the treatment and prevention of Alzheimer's disease, or Alzheimer's. In addition to its existing product candidates, it utilizes a structure-based drug discovery platform, and leverage expertise to create novel, potent and selective product candidates. The Company utilizes Contour to discover and develop product candidates for validated therapeutic targets against which the industry has traditionally struggled to develop drugs due to challenges related to potency, selectivity, pharmacokinetics, or patentability issues. Contour's computational software uses artificial intelligence and sophisticated algorithms to model the assembly of molecular fragments, which are chemical structures consisting of one to several atoms, into fully elaborated, drug-like structures that precisely fit each target's 3-dimensional binding site. It faces potential competition from pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions.

Contact Information

Website: www.vitaepharma.com
Email: mike@minefinders.com
Main Phone: +1 215 461-2000
Address: 502 West Office Center Drive
State: PA
City / Town: Fort Washington
Country: USA
Postal Code: 19034

Issuer Information

Exchange: NSD
CEO: Mr. Mark H. Bailey
Employees: 56
NAICS: Pharmaceutical Preparation Manufacturing(325412)
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume 0 52 Wk Hi 21.04 52 Wk Low 4.08
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 28,841,067.00 EPS (TTM) N/A PE Ratio N/A Exchange NSD
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 0
Number of Buys 0 0
Number of Sells 0 0
Net Activity 0 0
Last 10 Buys Shares
Arthur Fratamico 1,000
Peter Barrett 1,000
Bryan E. Roberts 1,000
Bryan E. Roberts 1,000
Bryan E. Roberts 1,000
Last 10 Sell Shares
Jeffrey S. Hatfield 1,000
Donald J. Hayden 1,000
Donald J. Hayden 1,000
Jeffrey S. Hatfield 1,000
Donald J. Hayden 1,000
Donald J. Hayden 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 21 21 21 21
Low Target Price Estimate 10 10 10 10
Mean Target Price Estimate 18.25 18.25 18.25 18.25
Standard Deviation 5.5 5.5 5.5 5.5
Date of Most Recent Estimate 09/20/16 09/20/16 09/20/16 09/20/16
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 0 0 5 6
Moderate Buy 0 0 0 0
Hold 5 6 1 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 3 3 1.33 1